Molecular Imaging: A Market Coming of Age

Date: August 22, 2011
Pages: 290
Price:
US$ 1,740.00
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: MB866505DCEEN
Leaflet:

Download PDF Leaflet

Molecular Imaging: A Market Coming of Age
  • Critical review of the market conditions, trends and challenges
  • Unique market forecasts to 2015 by major sector
  • Comprehensive and detailed competitive analysis of 75 leading players

The early vision for molecular imaging (MI) was that it would revolutionise clinical diagnostics and pharmaceutical research, allowing disease to be explored and identified with greater accuracy and long before physical symptoms were experienced. But economic recession and technical challenges have taken their toll on the speed at which that vision has become reality - until now. While for many years MI delivered more promise than profits, the signs are that new products, applications and increasing clinical/health payer acceptance will see the market accelerate in the medium term to achieve global sales of US$6 billion by 2015.

Strong fundamentals are driving growth

Despite cost pressures from reduced capital spending and lower reimbursement for some procedures, the MI market fundamentals remain solid and there are strong opportunities for growth within the MI industry. The increasing incidence of cancer, cardiovascular and neurological diseases means that demand for faster and more accurate diagnosis, as well as drug development and pre-clinical study efforts, will continue to accelerate in the coming years. In addition, imaging technologies will become more widely adopted as clinical evidence is established as to their benefits, and new technological innovations continue to be brought to market, particularly related to the MI of cancer and neurological diseases. In addition, the current lack of penetration for nuclear and molecular imaging in emerging economies such as China, India and Brazil is driving demand in these regions, where new nuclear imaging facilities are being set up and lower-cost systems are in demand.

Corporate manoeuvres

The industry is still developing but already companies in the medical diagnostic imaging equipment business such as Philips, Siemens and GE, and in the radiopharmaceutical and contrast agent market such as GE, Bracco, Covidien, Bayer and Lantheus Medical Imaging are taking leading positions. And opportunities for big Pharma are not being missed, with both Eli Lilly and AstraZeneca actively involved. As the market develops, expect more consolidation in the tussle for dominance.

This new report provides unique 5-year market forecasts

Molecular imaging is still a developing sector and the question is often asked what it will be worth commercially. For the first time, this report provides a 5-year evaluation of the market’s prospects and provides year-by year growth for key sectors:
  • Nuclear Imaging
  • Pre-Clinical Imaging Systems
  • Molecular Imaging End-Use Products Market
  • Radiopharmaceuticals

This report easily answers key business questions such as:
  • Which sector of the molecular imaging market is expected to achieve global sales of US$3.5 billion in 2015?
  • What steps are being taken to ensure availability of the key istope Mo-99?
  • How is Gallium-68 being used to better understand cancer cell migration?
  • What advantages does PET have over other imaging technologies?
  • What challenges must be overcome to meet growing demand in emerging markets and how is this influencing developers?
  • Which European company is developing nanoprobes which identify the expression of the HER2 protein and with whom is it collaborating?
  • Which US company was granted a European patent in March 2011 for its contrast agent used in the diagnosis of deep vein thrombosis?
  • Now approved in the US and EU, does Digirad’s portable nuclear system mark a move to distributed MI technologies?
  • Only one company offers a full suite of MI products – is this a competitive advantage and does it represent an opportunity for further entrants to provide whole-market service?

A complete analysis packed with market analysis, sector forecasts to 2015 and detailed company evaluations

This report delivers the most complete and critical appraisal of the market, products and companies operating in this fast-growing health sector

EXECUTIVE SUMMARY


BACKGROUND

Applications of MI
Neurological Disease
Oncology
Cardiovascular Disease
MI for Drug Development

MI Modalities

Hybrid MRI/PET Imaging
Tracers and Radiopharmaceuticals

CURRENT MARKET DYNAMICS

Major Market Players
Recent Developments in the SPECT Market
Recent Developments in the PET Market
Reimbursement and Regulatory Approval Issues

MARKET OUTLOOK

Molecular Imaging: Market Drivers, Restraints &
Future Opportunities
Market Forecasts 2010 -2015
Nuclear Imaging
Pre-Clinical Imaging Systems
Molecular Imaging End-Use Products Market
Radiopharmaceuticals
Emerging Technologies
The Role of Academic Institutions
Collaborative Development Efforts
New Imaging Modalities

MOLECULAR IMAGING COMPANIES

For each company an evaluation is made of their financial performance/status, products, research areas and significant deals or strategic partnerships

ABT Molecular Imaging
ABX
Advanced Accelerator Applications
Advanced Cyclotron Systems
Advanced Medical Isotope
Affibody
Agenix
AntiCancer
Aleres Pharmaceuticals
Aposense
ART Advanced Research Technologies
Astellas Pharma
AstraZeneca
Atreus Pharmaceuticals
Avid Radiopharmaceuticals (Eli Lilly)
Bayer HealthCare Pharmaceuticals
Bioscan
Biospace Lab
Bracco
Bruker Biospin
BV Cyclotron Vu
Caliper Life Sciences
Cardinal Health
Carestream Health
CellPoint
Covidien
Cyclopharma
Digirad
Dilon Diagnostics
DRAXIMAGE
Eckert & Ziegler
Eczacibaşi-Monrol Nuclear Products
Erigal
GE Healthcare
Guerbet
Hamamatsu Photonics
IBA (Ion Beam Applications)
Imaging Diagnostic Systems
ImaginAB
Immunomedics
INDEC Systems
IntraMedical Imaging
Kereos
Lantheus Medical Imaging
Lightools Research
Mediso Medical Imaging Systems
MiLabs
Molecular Insight Pharmaceuticals
Naviscan
Neoprobe
Neurologica
Nordion
Novelos Therapeutics (Cellectar)
NuView Life Sciences
OncoVision
PerkinElmer
Pharmalucence
Philips Healthcare
Positron
Proportional Technologies
Scintomics
Seno Medical Instruments
Shimadzu
Siemens Healthcare
Sofie Biosciences
Spectrum Dynamics
Triad Isotopes
UltraSPECT
United Pharmacy Partners
Visualsonics (Sonosite)
Wilex

TABLE OF FIGURES

Diagnostic Imaging Systems Market by Modality, 2010
Medical Imaging Market, 2005-10 (US$b)
Nuclear Imaging Equipment Market, 2007-10 (US$b)
Molecular Imaging Market by End-Use Product Type, 2010
Nuclear Imaging Equipment Market, 2010-15E (US$m)
Pre-Clinical Imaging Systems Market, 2010-15E (US$m)
Radiopharmaceuticals Market, 2010-15E (US$m)
Molecular Imaging End-Use Products Market, 2010-15E (US$m)
Astellas Pharma Cardiac Imaging Sales, 2008-10 (US$m)
Caliper Life Sciences - Revenue by Division, 2010
Covidien’s Imaging Sales, 2006-10 (US$m)
Digirad - Revenue by Division, 2010
Eckert & Ziegler - Revenue by Product Segment, 2010
GE Healthcare - Revenue by Product, 2010
IBA - Revenue by Business Unit, 2010
Lantheus Medical Imaging: Cardiolite Sales, 2008-10 (US$m)
Nordion - Revenue by Segment, 2010
Nordion: Medical Isotope Sales and Earnings, 2008-10 (US$m)
Philips Healthcare - Revenue by Segment, 2010
Philips Healthcare - Revenue by Region, 2010
Siemens Healthcare: Sales by Division, 2010

Trends and challenges – make sure you are fully briefed on the issues which are shaping the market...

Are the cost benefits of molecular imaging being recognised?

Health payers, in the midst of an economic downturn, are focused on limiting immediate costs and this has impacted expansion and reimbursement of several imaging procedures. But advanced imaging enables detection and diagnosis at earlier stages of disease development, enabling treatment to begin before disease becomes systemic or established and reducing costs for invasive surgery or later-stage drug treatments. Similarly, there is much concern over the cost of new drugs, many of which may be used without the most accurate diagnostic insight into the underlying pathology of the disease. Molecular imaging’s advanced ability to evaluate disease at the molecular level has a critical role to ensure that only appropriate medicines are administered. Evidence is still building, but health payers would be wise to consider future molecular imaging technology as a benefit and not a cost in their financial plans.

Molecular Imaging – only for the big boys?

Although MI technologies hold great promise and market potential, there are significant barriers to market entry for companies, including the significant capital investments required to develop such products and get them through the lengthy and costly regulatory approval process. Adding to the challenge has been the difficult economic environment in recent years, which has limited the ability of start-up companies to raise capital from financial institutions or attract investment. Despite a difficult market for start-ups, the strong growth potential of MI technologies is providing good opportunities for companies with cash or financing available to them to add to their MI operations or enter this market, both through acquisitions or by licensing technologies from companies that cannot afford to commercialise them themselves.

A case in point...

Alzheimer’s disease imaging is currently a major area of opportunity, both in terms of helping to achieve a clinical diagnosis for a condition that can currently only be diagnosed at autopsy and also for pharmaceutical companies developing drugs to treat the condition. Previously privately-held, Avid Radiopharmaceuticals was acquired by the multi-national pharmaceutical company, Eli Lilly and Company, in December 2010. Avid’s lead MI agent, Amyvid, is being developed to diagnose Alzheimer’s disease and is expected to become the first MI agent for Alzheimer’s disease to be FDA-approved later in 2011. There are plenty of examples where smaller companies have ceased trading or changed status – investment capital is crucial to innovation, and how much of that comes from big Pharma will be closely watched.

In research...new imaging modalities

MI is driven by technical innovation. New modalities in research include GMI’s dual modality MRI/SPECT system, Philip’s Magnetic Particle Imaging platform for imaging nanoparticle concentrations in blood and GE’s 13C Hyperpolarised metabolic MR, which produces real-time, quantitative data regarding the presence and aggressiveness of tumours.

About the Author

This report has been researched and written by senior Espicom medical market analyst Joanne Maddox. For over 10 years she has played a pivotal role in tracking trends in medical device and equipment markets and companies. A former editor of Medical Device Companies Analysis she has also written Medical IT: Understanding the major players and products, All Change in the Advanced Woundcare Market and Point of Care Diagnostics: Players, Products and Prospects.
EXECUTIVE SUMMARY

BACKGROUND
  Applications of MI
    Neurological Disease
    Oncology
    Cardiovascular Disease
    MI for Drug Development
  MI Modalities
    Hybrid MRI/PET Imaging
    Tracers and Radiopharmaceuticals
CURRENT MARKET DYNAMICS
  Fig.1: Diagnostic Imaging Systems Market by Modality, 2010
  Fig.2: Medical Imaging Market, 2005-2010 (US$ billion)*
  Fig.3: Nuclear Imaging Equipment Market, 2007-2010 (US$ billion)*
  Fig.4: Molecular Imaging Market by End-Use Product Type, 2010
  Competitive Landscape
    Barriers to Market Entry and Market Consolidation
  Recent Developments in the SPECT Market
    Molybdenum-99 Isotope Supply Issues
      New Supply Initiatives
      Alternative Tc-99m Production Methods
  Recent Developments in the PET Market
    Alzheimer’s Disease PET Imaging
      National Institute on Aging/Alzheimer’s Association Diagnostic Guidelines for Alzheimer’s Disease 18
      Products in Development
  Reimbursement and Regulatory Approval Issues
MARKET OUTLOOK
  Molecular Imaging: Market Drivers, Restraints & Future Opportunities
  Fig.5: Nuclear Imaging Equipment Market, 2010-2015E (US$ million)*
  Fig.6: Pre-Clinical Imaging Systems Market, 2010-2015E (US$ million)
  Fig.7: Radiopharmaceuticals Market, 2010-2015E (US$ million)
  Fig.8: Molecular Imaging End-Use Products Market, 2010-2015E (US$ million)*
  Emerging Technologies
    The Role of Academic Institutions
    Collaborative Development Efforts
    New Imaging Modalities
      MRI/SPECT
      Philips’ Magnetic Particle Imaging
      GE Healthcare and 13C Hyperpolarised Metabolic MR

MOLECULAR IMAGING COMPANIES

ABT MOLECULAR IMAGING
ABX
ADVANCED ACCELERATOR APPLICATIONS
  Recent Events
  Products
  Current Alliances
    Institut Curie
    IASON GmbH
    European Molecular Imaging Manufacturers Association
    Bracco
  Financial Performance
    Fig.9: Advanced Accelerator Applications - Sales by Segment, 2010
ADVANCED CYCLOTRON SYSTEMS
  Recent Events
  Products
    TR 24 Cyclotrons
    TR 30 Cyclotrons
    TR PET Cyclotrons
  R&D Programme: Cyclotron Production of Tc-99m in Canada
  Current Alliances
    TRIUMF
    GE Healthcare
ADVANCED MEDICAL ISOTOPE CORPORATION
  Products in Development
    US Production of Molybdenum-99
  Financial Performance
    AMIC - Operating Results, 2006-2010 (US$ thousand)
    Latest Results
AFFIBODY
  MI Research Studies
  Alliance with GE Healthcare
AGENIX
  ThromboView
ALSERES PHARMACEUTICALS
  Altropane
    Altropane for Dementia with Lewy Bodies
ANTICANCER
  Research and Development
    Gene-Based Fluorescence-Labelling Technology for Cancer Surgery
  Current Alliances
    UVP
    Caliper Life Sciences
    INDEC Systems
    Olympus
APOSENSE
  [18F]-ML-10 and EarliTest
    Clinical Trial Results
  Current Agreements
    University of Pittsburgh
    Roche
    IBA
    GlaxoSmithKline
    Sigma-Aldrich
ART ADVANCED RESEARCH TECHNOLOGIES
  ART: Recent Events
  Products
    Optix MX3
    SoftScan Optical Breast Imaging System
    Clinical Trial Results
    Fenestra Contrast Agents
ASTELLAS PHARMA
  Lexiscan (regadenoson)
    Clinical Trial Results
  Adenoscan (adenosine injection)
  Cardiac Imaging Revenue
    Fig.10: Astella Pharma Cardiac Imaging Sales, Fiscal 2008-2010 (US$ million)
ASTRAZENECA
  [11C]AZD2184
  [18F]-AZD4694
ATREUS PHARMACEUTICALS
    Alliance with Advanced Proteome Therapeutics
AVID RADIOPHARMACEUTICALS (ELI LILLY)
  Amyvid (florbetapir F 18 injection)
  18F-AV-133
  Current Alliances
    PETNET Solutions (Siemens Healthcare)
    Adler Institute for Advanced Imaging
    Bayer HealthCare Pharmaceuticals
BAYER HEALTHCARE PHARMACEUTICALS
  Recent Key Events
  Research and Development
    Florbetaben PET Tracer
    BAY 86-4367 for Prostate Cancer PET Imaging
    BAY 94-9392 for Tumour Imaging
  Current Alliances
    Ion Bean Applications
    AC Immune
    Celera (Quest Diagnostics)
    Hamamatsu Photonics
    Nagasaki University
    FutureChem
    Avid Radiopharmaceuticals (Eli Lilly)
    Taisho Pharmaceutical, Nihon Nohyaku and National Institute of Radiological Sciences, Japan
    Stanford University
    Philips
      Magnetic Particle Imaging Technology Consortium
  MEDITRANS
BIOSCAN
  NanoSPECT/CT and NanoPET/CT
    NanoSPECT/CT and NanoSPECT/CTPlus
    NanoPET/CT
  HiSPECT
  In Development - Pre-clinical PET/MRI System
BIOSPACE LAB
  Recent Key Events
  Products
    Photon Imager System
    Gamma Imager
    Beta Imager
    Micro Imager
    Beta Microprobe
    M3 Vision Software
  Current Alliances
    LabChina Co Ltd and LabChina Taiwan Co Ltd
    Promega France
BRACCO
  Products
    CardioGen-82
  Research and Development
  Current Alliances
    Rete Ventures
    Nordion
    Advanced Accelerator Applications (AAA)
    ImaRx Therapeutics
    VisualSonics
  MEDITRANS
BRUKER BIOSPIN
  Recent Key Events
  Products
    BioSpec Pre-Clinical MRI
    BioSpec 150/11
    BioSpec 117/16
  Icon
  ClinScan
  PharmaScan
    MRI CryoProbe
    ParaVision 5.0 Software
  Current Alliances
    Philips
      Magnetic Particle Imaging Technology Consortium
    Aspect Imaging
    University of York, UK
    Iseult Programme
      BioSpec 170/25
    Siemens
BV CYCLOTRON VU
  Alliance with IBA Group
  Alliance with VU University Medical Centre
CALIPER LIFE SCIENCES
  Recent Key Events
  Pre-Clinical Imaging Products
    IVIS Imaging Systems
      Living Image 4.0 Software
      Reagents and Accessories
    Quantum FX MicroCT System
    Living Image Multi Modality Software Module and the Mouse Imaging Shuttle
    Maestro MI Systems
      Maestro Dynamic
      Maestro EX
      Maestro
  Current Alliances
    VisEn Medical (PerkinElmer)
    DuPont
    AntiCancer
    Invitrogen
    Stanford University
    Massachusetts General Hospital
  Litigation with Carestream Health
  Financial Performance
    Fig.11: Caliper Life Sciences - Revenue by Division, 2010
    Latest Results
    Outlook
CARDINAL HEALTH
  Recent Key Events
  Products
    Cardiac Imaging Agents
  Current Alliances and Collaborations
    ProVision Healthcare
    University of Washington
    American College of Radiology Imaging Network
    Ohio Third Frontier and Ohio State University
    IBA Group
    Eckert & Ziegler
    GE Healthcare
    Syntermed
    Neoprobe
    Lantheus Medical Imaging
CARESTREAM HEALTH
  Albira PET/SPECT/CT System
      In Vivo Imaging Solutions
    In-Vivo MS FX PRO
    In-Vivo FX Pro
    In-Vivo F PRO
    In-Vivo Imaging System FX
    In-Vivo DXS PRO
    Carestream Molecular Imaging Software
  Litigation with Caliper Life Sciences
CELLPOINT
  EC Technology
    99MTC-EC-G FOR ONCOLOGY
    99MTC-EC-METRONIDAZOLE FOR STROKE
    Tumour Hypoxia
  N4 Technology
  Dual Agent Technology
  Beta Cell Technology
  Current Alliances
    Eli Lilly and Company
    Philips Healthcare
    M D Anderson Cancer Center
COVIDIEN
    Fig.12: Covidien’s Imaging Sales, 2006-2010 (US$ million)
    Recent Key Events
  Radiopharmaceuticals
    Mo-99 Supply
  Current Alliances
    Positron
    Institute of Atomic Energy, Poland
    Babcock & Wilcox
    Siemens
    BV Cyclotron VU
CYCLOPHARMA
DIGIRAD
  Recent Key Events
  Products
    ergo
    Cardius XPO Series
      Cardius X-ACT
    c.pax
  Alliance with Dilon Diagnostics
  Financial Performance
    Digirad - Operating Results, 2006-2010 (US$ million)
    Fig.13: Digirad - Revenue by Division, 2010
    Latest Results
DILON DIAGNOSTICS
    Recent Key Events
  Dilon 6800 Gamma Camera
  Dilon 6800 Acella
  GammaLoc
    Recent BSGI Clinical Trial Results
  Current Alliances and Contracts
    Digirad
    Philips
    Terason Ultrasound
    PenRad Mammography Information Systems
DRAXIMAGE
  Products
    DRAXIMAGE Sestamibi
  Current Alliances
    Guerbet
    GE Healthcare
ECKERT & ZIEGLER
  Recent Key Events
  Products and Services
    Bioscan Analytical and Radiochemistry Products
  Contracts and Alliances
    Euromedic International
    ZAG Zyklotron
    Polish Medical University of Gdansk
    Cardinal Health
  Financial Performance
    Eckert & Ziegler Operating Results, 2007-2010 (EUR million)
    Fig.14: Eckert & Ziegler - Revenue by Product Segment, 2010
    Latest Results and Outlook
ECZACIBAŞI-MONROL NUCLEAR PRODUCTS
  Alliance with IBA Group
ERIGAL
EUSA PHARMA
  ProstaScint
    Clinical Study Results
  FLUOROPHARMA MEDICAL
  Product Pipeline
    CardioPET
    BFPET
    VasoPET
    AZPET
GAMMA MEDICA-IDEAS
  LumaGEM Molecular Breast Imaging System
    Clinical Study Results
  Triumph Pre-Clinical Imaging
    LabPET Solo
  Research and Development
    SPECT/MRI System
  Current Alliances
    Mayo Clinic
    GE Healthcare
    SII NanoTechnology
    Exxim Computing
GE HEALTHCARE
  Recent Key Events
  Products
    PET/CT +MR Imaging Platform
    Nuclear Medicine
      Discovery NM630 SPECT System
      Alcyone Technology SPECT/CT Products
      Infinia Hawkeye SPECT/CT
      Millennium and Infinia General Purpose Systems
      Ventri Cardiology System
  PET/CT
    Optima PET/CT
    Discovery PET/CT
  Pre-Clinical Systems
    Triumph II
    GE eXplore CT
    eXplore speCZT
    eXplore Locus SP
    eXplore Locus
    LabPET Solo
  PET Radiopharmacy Products
  Nuclear and Molecular Imaging Agents
    AdreView (Iobenguane I 123) Injection
    DaTscan (Ioflupane I 123 Injection)
    Myoview
    Ceretec
    DRYTEC
    Hexvix/Cysview
  Research and Development
    Research Projects
      MI Agents
      13C HYPERPOLARISED METABOLIC MR
      Fluorescent Imaging
  Research Collaborations
    ImaginAb
    The Medical College of Wisconsin
    Immunomedics
    Brigham and Women’s Hospital
    Gamma Medica-Ideas
    University of Pittsburgh
    PredictAD Project
    Merck & Co
    Fraunhofer Institut für Toxikologie und Experimentelle Medizin
    University of Washington
    Affibody
    Roche
    University of Illinois at Chicago
  Distribution and Other Agreements
      Rapidscan Pharma Solutions
    Advanced Cyclotron Systems Inc
    Neuroimage
    Joint Venture with Nycomed
    Nihon Medi-Physics Joint Venture with Sumitomo Chemical
    Photocure
    IntraMedical Imaging
    Lantheus Medical Imaging
  Financial Performance
    GE Healthcare Operating Results, 2005-2010 (US$ million)
    Fig.15: GE Healthcare - Revenue by Product, 2010*
GUERBET
  Research and Development
  Current Alliances and Collaborations
    Gallimed Project - Nordion and Cyceron
    IMAkinib
    DRAXIMAGE
    Iseult Programme
    MediTrans
HAMAMATSU PHOTONICS
  Products
    Animal PET Scanner SHR-7700
  Research and Development
    Reflectance Diffuse Optical Tomography
  Alliances
    Bayer HealthCare Pharmaceuticals
  IBA (ION BEAM APPLICATIONS)
    Recent Key Events
  MI Products and Services
    Radiopharmaceuticals
      New Product Approvals
    Cyclotron Equipment
  Research and Development
  Current Alliances and Contracts
    KeyMarker Consortium
    Servicio Andaluz de Salud, Spain
    Dehnel - Particle Accelerator Components and Engineering
    CEA, France, and IRE, Belgium
    Bayer HealthCare Pharmaceuticals
    Bio Molecular Industries
    SISORA
    Aposense
    Eczacıbaşı-Monrol Nuclear Products
    BV Cyclotron VU
    Hae Dong Co Ltd
    Lantheus Medical Imaging
    Wilex
  Financial Performance
    IBA - Operating Results, 2006-2010 (EUR million)
    IBA - Revenue by Business Unit, 2006-2010 (EUR million)
    Fig.16: IBA - Revenue by Business Unit, 2010
    Latest Results
IMAGINAB
  Recent Key Events
  Research Projects
  Current Alliances
    GE Imanet
    Oxford BioMedica
    KeyMarker Consortium
    University of California, Los Angeles
    Dainippon Seiki
    Singapore’s Agency for Science, Technology and Research
    GlaxoSmithKline
    BZL Biologics
IMAGING DIAGNOSTIC SYSTEMS
  CTLM System
    Fluorescence and Molecular Imaging
  Laser Imager for Lab Animals (LILA)
  Financial Performance
    IDSI - Operating Results, 2006-2010 (US$)
    Latest Results
IMMUNOMEDICS
  LeukoScan
  Research and Development
    TF2 for Colorectal Cancer Imaging and Radioimmunotherapy
    Peptides for Imaging
  Current Alliances
    GE Healthcare
    Agenix
INDEC SYSTEMS
INTRAMEDICAL IMAGING
KEREOS
  Product Pipeline
    KI-0001
    KI-0003
  R&D Collaborations
    Washington University
    The Dow Chemical Company
  LANTHEUS MEDICAL IMAGING
  Recent Key Events
  Products
    ABLAVAR (Gadofosveset Trisodium)
    Cardiolite
    TechneLite (Technetium Tc99m Generator)
  Research and Development
    Flurpiridaz F
    LMI 1195 for Cardiac PET Imaging
    BMS 753951
  Current Alliances and Contracts
    Nordion
    Novation
    NTP Radioisotopes
    Amerinet
    Institute for Radioelements, Belgium, and Nuclear Research Institute, Czech Republic
    Cardiolite and TechneLite Distribution Agreements
    Australian Nuclear Science and Technology Organisation
    IBA Group
  Financial Performance
    Lantheus Medical Imaging - Operating Results, 2007-2010 (US$ million)
    Lantheus Medical Imaging - Sales by Key Product Line, 2008-2010 (US$ million)
    Fig.17: Lantheus Medical Imaging - Revenue by Product Line, 2010
    Lantheus Medical Imaging - Sales by Region, 2008-2010 (US$ million)
    Fig.18: Lantheus Medical Imaging - Sales by Region, 2010
    Latest Results
LIGHTOOLS RESEARCH
  MI Products
    Pan-A-See-Ya Panorama
    Macro-Illumination Imaging System
    Macro-Imaging System Plus
  MEDISO MEDICAL IMAGING SYSTEMS
    AnyScan SPECT-CT-PET
    Nucline Gamma Cameras
    Pre-Clinical PET/MRI Collaboration with Aspect Imaging
MILABS
  Products
    VECTor
    U-SPECT-II/CT
    U-CT
    U-SPECT II Scanners
  Current Alliances
    SkyScan
    Mid-Atlantic Imaging Services
MOLECULAR INSIGHT PHARMACEUTICALS
  Recent Key Events
  Research and Development
    Zemiva
    Trofex
      Trofex for Treatment Monitoring
    Hypoxia Imaging Radiopharmaceuticals
    Tc-99m-Labelled Peptide for Targeting Neuroendocrine Tumours
  Current Alliances
    Nordion
NAVISCAN
  Recent Key Events
    Positron Emission Mammography Scanner
    PEM Clinical Study Results
    Stereo Navigator
    MIMviewer PEM
  Current Alliances
    Chindex Medical
    Tecnologie Avanzate
    Neoprobe
    Nuclear Medicine Distributors
    SCETI
    Hae Dong Co Ltd
    MIMVista
NEOPROBE
  Recent Key Events
  Gamma Detection Products
  Research and Development
    Lymphoseek
      Breast Cancer and Melanoma
      Head and Neck Squamous Cell Carcinoma
    RIGScan CR
  Current Alliances and Licences
    Naviscan
    Dow Chemical Company
    Laureate Pharma
    Cardinal Health
    University of California, San Diego
  Financial Performance
    Latest Results
NEUROLOGICA
NORDION
  Recent Key Events
  Products
    Medical Isotopes
      Medical Isotope Supply Issues
  Current Alliances
    Lantheus Medical Imaging
    The Open Joint Stock Company “Isotope”
    Gallimed Project - Guerbet and Cyceron
    Bracco
    TRIUMF and the University of British Columbia
    University of Ottawa Heart Institute
    Molecular Insight Pharmaceuticals
  Financial Performance
    Nordion - Results from Continuing Operations, 2008-2010 (US$ million)
    Fig.19: Nordion - Revenue by Segment, 2010
    Nordion - Sales and Earning by Segment, 2008-2010 (US$ million)
    Medical Isotope Segment Results
    Fig.20: Nordion: Medical Isotope Sales and Earnings, 2008-2010 (US$ million)
    Latest Results
NOVELOS THERAPEUTICS (CELLECTAR)
  124I-CLR1404 (LIGHT)
NUVIEW LIFE SCIENCES
  Alliance with Thomas Jefferson University - VPAC1 For Imaging Prostate Cancer
  NVB64-PET for Breast Cancer Diagnosis
ONCOVISION
  Albira PET/SPECT/CT System
  Mammi Breast PET Imaging System
PERKINELMER
  Recent Key Events
  Fluorescence Molecular Tomography Imaging Systems
    Multispecies Imaging Module
  Imaging Agents
  Current Alliances
    MosaMedix
    Cambridge Research & Instrumentation (Caliper Life Sciences)
    Merck
PHARMALUCENCE
  MI Products
PHILIPS HEALTHCARE
  Recent Key Events
  Nuclear Medicine Products
    Ingenuity TF PET/MR
    PET/CT
      TruFlight Select PET/CT
      Ingenuity TF PET/CT
      Gemini PET/CT
  SPECT/CT Systems
    BrightView XCT
    BrightView X
    BrightView SPECT
    Precedence SPECT/CT
    SKYLight
    CardioMD
    Dilon Diagnostics’ Dilon 6800 Gamma Camera
  IntelliSpace Portal
  Extended Brilliance Workspace
  JETStream Workplace
  Pre-Clinical Imaging
    Imalytics Workspace
  Research and Development
    Research Establishments
      High Tech Campus
    Molecular Imaging R&D Projects
      Magnetic Particle Imaging
      Medical Optical Imaging
    Research Alliances
      Eindhoven University of Technology & the Sonodrugs Project
      University of Washington Medical Center
      VU University Medical Center
      Bruker BioSpin
      Bayer HealthCare Pharmaceuticals
      CellPoint
  Distribution and Licensing Agreements
    ROSATOM
    Dilon Diagnostics
    Bioscan
    Sun MicroSystems
  Financial Performance
    Philips Healthcare: Operating Results, 2007-2010 (EUR million)
    Fig.21: Philips Healthcare - Revenue by Segment, 2010
    Fig.22: Philips Healthcare - Revenue by Region, 2010
  POSITRON
    Recent Key Events
  Products
    PosiRx
    Attrius Cardiac PET Scanner
    Tech-Assist
    Radiopharmaceuticals
  Current Alliances
    Covidien
    Technology Imaging Services
    MedAxiom
  Financial Performance
    Positron - Operating Results, 2006-2010 (US$ thousand)
    Latest Results
PROPORTIONAL TECHNOLOGIES
  Cu-62 Micro-generator
  Products in Development
    PET Camera for Breast Imaging
    PET Camera for Small Animal Studies
SCINTOMICS
  Products
    Hotbox-III (HB-III)
    GallElut
    GRP Modules
    μ-ICR
    InViala
  In Development
SENO MEDICAL INSTRUMENTS
SHIMADZU
  MI Products
    PET Systems
    PET/CT Systems
    Clairvivo Pre-Clinical PET System
  Research Agreement with the National Cancer Center, Tokyo, Japan
  SIEMENS HEALTHCARE
  Recent Key Events
  Molecular Imaging and PET Products
    Biograph mMR MRI-PET System
    PET/CT
      Biograph mCT 20 Excel
      Biograph mCT
      Biograph TruePoint PET/CT
      syngo Dynamic PET with Myocardial Blood Flow
    SPECT and SPECT/CT Systems
      Symbia TruePoint SPECT/CT Systems
      SPECT Systems
      Symbia.net
    MI Workstations and Software
      syngo.via
      syngo MI Workplace
    Pre-Clinical Imaging
      Inveon
      microPET Focus
    Biomarkers
      Explora Radiochemistry Modules
      Eclipse Cyclotrons
      PETNET Solutions’ PET Radiotracers
  R&D Activities
    Siemens Molecular Imaging Biomarker Research
      [18F]-SMIBR-W372 Biomarker
      CA-IX Biomarker
      HX4 Biomarker
  Research Agreements
    University of Texas M D Anderson Cancer Center
    Iseult Programme and Commissariat à l’Energie Atomique
    Massachusetts General Hospital
  Supply, Distribution and Licensing Agreements
    Avid Radiopharmaceuticals (Eli Lilly)
    Lantheus Medical Imaging
    Covidien
    Medical University of South Carolina
    Cleveland Clinic
    Bruker BioSpin
    University of Muenster
  Financial Performance
    Siemens Healthcare - Operating Results, 2006-2010 (EUR million)
    Siemens Healthcare - Imaging and IT Division Results, 2006-2010 (EUR million)
    Fig.23: Siemens Healthcare Sales by Division, 2010
    Latest Results
SOFIE BIOSCIENCES
  Genisys4
  18F-FAC PROBES
  ELIXYS
SPECTRUM DYNAMICS
  D-SPECT Cardiac Imaging System
TRIAD ISOTOPES
ULTRASPECT
UNITED PHARMACY PARTNERS
VISUALSONICS (SONOSITE)
  Recent Key Events
  Products
    Vevo LAZR Photoacoustic Imaging System
    Vevo 2100
    Vevo
      Vevo SoniGene
  MicroMarker Contrast Agent Kits
  Mauna Kea Technologies’ Pre-Clinical Imaging Technologies
    Cellvizio LAB
    NeuroPak Deep Brain Imaging System
  Current Alliances
    Mauna Kea Technologies
    Seno Medical Instruments
    Bracco
    University of Virginia
WILEX
  Redectane
  Alliance with IBA Group

APPENDICES

APPENDIX 1 - LIST OF ABBREVIATIONS
APPENDIX 2 - REPORT METHODOLOGY
Skip to top


Ask Your Question

Molecular Imaging: A Market Coming of Age
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: